Oppenheimer's 26th Annual Healthcare Conference Provides Investors With Access To More Than 140 Public And Private Healthcare Companies

Dec 10, 2015, 09:30 ET from Oppenheimer & Co. Inc.

NEW YORK, Dec. 10, 2015 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings Inc., hosted its 26th Annual Healthcare Conference at The Westin New York Grand Central in New York City on December 8 – 9, 2015. The event featured management presentations from more than 140 public and private companies across the healthcare industry, including Cerner, OPKO Health, Medicines Company, Medtronic, HCA, Cigna, Seattle Genetics, Mallinckrodt and Intercept Pharmaceuticals.

The two-day conference, which also featured 1-on-1 and small group meetings, attracted more than 750 healthcare executives and investors across multiple sectors, including bio & specialty pharmaceuticals; biotechnology; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution; and healthcare providers and servicers.

"We are pleased to once again bring together so many healthcare companies and to provide investors with an opportunity to identify new products and trends within the entire healthcare sector," said Erica Moffett, Managing Director and Associate Director of Research.

Oppenheimer's conference schedule for 2016 is available at http://www.opco.com/conferences/index.aspx.

Conferences are only open to established institutional clients of Oppenheimer & Co. Inc. For more information, please contact your Oppenheimer & Co. Inc. institutional sales representative.

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.

SOURCE Oppenheimer & Co. Inc.



RELATED LINKS

http://www.opco.com